Autophagy-Targeting Chimera (AUTOTAC) is a novel bifunctional molecule that simultaneously binds to pathological protein aggregates and recruits autophagy machinery, enabling selective degradation of misfolded proteins implicated in neurodegenerative diseases [1].
AUTOTAC molecules consist of two functional domains:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9/10 | Novel mechanism; first-in-class small molecule degraders |
| Mechanistic Rationale | 9/10 | Strong proof-of-concept in cellular and animal models |
| Root-Cause Coverage | 9/10 | Directly targets protein aggregate root cause |
| Delivery Feasibility | 7/10 | Small molecules cross BBB; optimization ongoing |
| Safety Plausibility | 7/10 | Selects only pathological aggregates; avoids normal protein degradation |
| Combinability | 8/10 | Combines with upstream aggregation inhibitors |
| Biomarker Availability | 6/10 | Aggregate burden reduction measurable via PET |
| De-risking Path | 7/10 | Traditional small molecule development path |
| Multi-disease Potential | 9/10 | Platform technology applicable to multiple proteinopathies |
| Patient Impact | 8/10 | Disease-modifying potential through aggregate removal |
Total: 79/100
| Disease | Coverage | Evidence Strength |
|---|---|---|
| Alzheimer's Disease | AD(9) | Strong |
| Parkinson's Disease | PD(9) | Strong |
| ALS | ALS(8) | Strong |
| FTD | FTD(8) | Moderate |
| Aging | Aging(7) | Moderate |